Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient‐derived primary prostate cells

Abstract

Given that the drugs in the database are extremely well-characterized and that the patient-derived cells are easily scalable for high throughput drug screening, this combined in vitro and in silico approach may significantly advance personalized PCa treatment and for other cancer applications.